Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy

The purpose of this study is to determine whether it is feasible to administer high-dose epirubicin (135 mg m(−2)) combined with a fixed dose of cisplatin every 2 weeks with G-CSF support in patients with metastatic non-small-cell lung cancer (NSCLC). Subsequently, the efficacy of the recommended do...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Huisman, C, Biesma, B, Postmus, P E, Giaccone, G, Schramel, F M N H, Smit, E F
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2001
Teme:
Regular Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363962/
https://ncbi.nlm.nih.gov/pubmed/11720428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.2013
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items